Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;8(3):166-178.
doi: 10.15171/mejdd.2016.29.

New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article

Affiliations
Review

New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article

Hedyeh Ebrahimi et al. Middle East J Dig Dis. 2016 Jul.

Abstract

Liver fibrosis is a potentially reversible response to hepatic insults, triggered by different chronic diseases most importantly viral hepatitis, alcoholic, and nonalcoholic fatty liver disease. In the course of the chronic liver disease, hepatic fibrogenesis may develop, which is attributed to various types of cells, molecules, and pathways. Activated hepatic stellate cell (HSC), the primary source of extracellular matrix (ECM), is fundamental in pathophysiology of fibrogenesis, and thus is the most attractable target for reversing liver fibrosis. Although, liver biopsy has long been considered as the gold standard for diagnosis and staging of hepatic fibrosis, assessing progression and regression by biopsy is hampered by its limitations. We provide recent views on noninvasive approaches including serum biomarkers and radiologic techniques.

Keywords: Diagnosis; Fibrosis; Genetic Therapy; Liver Cirrhosis; Pathogenesis; Therapeutics.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18. doi: 10.1172/JCI200524282DS1. - DOI - PMC - PubMed
    1. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH. et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257–65. doi: 10.1016/S0168-8278(02)00413-0. - DOI - PubMed
    1. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis. 2001;21:351–72. doi: 10.1055/s-2001-17556. - DOI - PubMed
    1. Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med. 2001;344:452–4. doi: 10.1056/NEJM200102083440610. - DOI - PubMed
    1. Falize L, Guillygomarc’h A, Perrin M, Laine F, Guyader D, Brissot P. et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44:472–7. doi: 10.1002/hep.21260. - DOI - PubMed

LinkOut - more resources